LGD-4033

From Infogalactic: the planetary knowledge core
Jump to: navigation, search
LGD-4033
240px
Systematic (IUPAC) name
4-[(2R)-2-[(1R)-2,2,2-trifluoro-1-hydroxyethyl]pyrrolidin-1-yl]-2-(trifluoromethyl)benzonitrile
Clinical data
Legal status
  • Investigational new drug
Routes of
administration		 Oral
Pharmacokinetic data
Biological half-life 24-36 hours [1]
Identifiers
CAS Number 1165910-22-4 YesY
ATC code none
PubChem CID: 44137686
UNII 1EJT54415A YesY
Chemical data
Formula C14H12F6N2O
Molecular mass 338.25 g·mol−1
  • FC([C@H](O)[C@H]1CCCN1C2=CC(=C(C#N)C=C2)C(F)(F)F)(F)F
  • InChI=1S/C14H12F6N2O/c15-13(16,17)10-6-9(4-3-8(10)7-21)22-5-1-2-11(22)12(23)14(18,19)20/h3-4,6,11-12,23H,1-2,5H2/t11-,12-/m1/s1
  • Key:OPSIVAKKLQRWKC-VXGBXAGGSA-N

LGD-4033 (now known as VK5211)[2] is an investigational selective androgen receptor modulator (SARM) for treatment of conditions such as muscle wasting and osteoporosis, discovered by Ligand Pharmaceuticals and currently under development by Viking Therapeutics.[3][4]

References

  1. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  2. ↑ VK5211 on BioCentury
  3. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  4. ↑ Viking Signs Broad Licensing Deal With Ligand Pharmaceuticals for Rights to Five Novel Therapeutic Programs


Retrieved from "https://infogalactic.com/w/index.php?title=LGD-4033&oldid=719252122"